Found 55 neurology trials
A listing of neurology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Healey ALS Platform Trial - Regimen F ABBV-CLS-7262
ABBV-CLS-7262 is a prodrug that is converted in vivo to the pharmacologically active parent compound A-1684909. A-1684909 is a central nervous system (CNS)-penetrant, eukaryotic translation initiation factor 2B (eIF2B) activator that attenuates the integrated stress response (ISR), a highly conserved cellular mechanism hypothesized to be important in the pathophysiology of …
Improving Sleep in the Neurology In-Patient Population
The research is being conducted to improve sleep in the inpatient neurology population by decreasing overnight interruptions and addressing environmental barriers to sleep in the hospital. If you agree to join this study, you will be asked to complete the following research procedures: wear an activity and sleep monitor (FitBit), …
FOLLOW-UP VESSEL WALL MR IMAGING TO EXPLORE SEX-DIFFERENCES OF INTRACRANIAL ARTERIAL WALL CHANGES AND INTRACRANIAL ATHEROSCLEROTIC PLAQUE TREATMENT EFFICACY
Mortality related to cardiovascular disease in the US is improving. Yet the rate of decline is less for women than for men. Women's health is unique due to the varying reproductive stages, and differences are further heightened by sex-specific molecular and cellular characteristics of the heart and vasculature. These biophysiological …
A Phase 3 Open-Label Multi-Center Trial to Evaluate the Long- Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-OLS)
This is a Phase 3, open-label, multi-center trial to evaluate the long-term safety, efficacy, and immunogenicity of up to four continuous treatment cycles of daxibotulinumtoxinA (DAXI) for injection at doses of 125 U, 200 U, 250 U, or 300 U in adults with isolated cervical dystonia (CD). Approximately 290 adult …
BEAT-MS Multiple Sclerosis Trial
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.All participants will be followed …
Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's …
Clinical Core Alzheimer's Disease Core Center (ABC)
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D.. We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data and biological samples, …
MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis
This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with …
The Parkinsons Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort
The purpose of this study is to continue to obtain information from people with and without Parkinson disease (PD) so that researchers may better understand how Parkinson disease progresses, in order to inform better treatments. The information collected in this study is for research and not for clinical care. This …
Please choose between Voice or SMS based delivery of verification code
or